{"id":"NCT02207413","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK23211381A) Manufactured With a New Process in Adults and Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-18","primaryCompletion":"2015-04-18","completion":"2015-04-18","firstPosted":"2014-08-04","resultsPosted":"2016-06-20","lastUpdate":"2018-06-06"},"enrollment":1886,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Influsplit Tetra™ vaccine produced by investigational process (IP)","otherNames":["Fluarix Tetra™","Fluarix Quadrivalent® (GSK2321138A)"]},{"type":"BIOLOGICAL","name":"Influsplit Tetra™ vaccine produced by licensed process (LP)","otherNames":["Fluarix Tetra™","Fluarix Quadrivalent® (GSK2321138A)"]}],"arms":[{"label":"Influsplit Tetra_IP Adult Group","type":"EXPERIMENTAL"},{"label":"Influsplit Tetra_LP Adult Group","type":"ACTIVE_COMPARATOR"},{"label":"Influsplit Tetra_IP 3-17y Group","type":"EXPERIMENTAL"},{"label":"Influsplit Tetra_LP 3-17y Group","type":"ACTIVE_COMPARATOR"},{"label":"Influsplit Tetra_IP 6-35m Group","type":"EXPERIMENTAL"},{"label":"Influsplit Tetra_LP 6-35m Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to demonstrate the acceptable safety profile and the immunological non-inferiority of the FLU D-QIV vaccine manufactured with this investigational process (FLU D-QIV Investigational Process \\[IP\\]) compared to FLU D-QIV manufactured with the current licensed process (FLU D-QIV Licensed Process \\[LP\\]).","primaryOutcome":{"measure":"Number of Subjects Aged 18-49 Years Reporting Solicited Local Adverse Events (AEs).","timeFrame":"During the 7-day (Days 0-6) post-vaccination period","effectByArm":[{"arm":"Influsplit Tetra_IP Adult Group","deltaMin":41,"sd":null},{"arm":"Influsplit Tetra_LP Adult Group","deltaMin":32,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":13,"exclusionCount":36},"locations":{"siteCount":53,"countries":["United States","Bangladesh","Czechia","France","Germany","Poland","Spain"]},"refs":{"pmids":["29669531"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":60},"commonTop":["Pain","Erythema","Swelling","Irritability","Cough"]}}